

# ST FRANCIS ST. GEORGE

HOSPITAL,  
INC.

3131 QUEEN CITY AVENUE, CINCINNATI, OHIO 45238 513/389-5000  
An Affiliate of St. Francis-St. George Health Services, Inc.

Technology Is Advanced. Traditions Are Continued.

July 8, 1985

United States Nuclear Regulatory Commission  
Region III  
799 Roosevelt Road  
Glen Ellyn, IL 60137

RE: NRC License #34-00789-01

Gentlemen:

I would like to request that we have our NRC License #34-00789-01 amended to add the physician, Dr. Thomas Morand, to the above license to utilize Group IV, brachytherapy sources, under the above license number.

Dr. Morand is currently licensed under License #34-13995-01, amendment #15; a copy of this is attached for your records.

Enclosed you will find a check in the amount of \$120 to cover this amendment. If you need additional information regarding this license, please contact me.

Your utmost attention to this request would be appreciated due to the fact that Dr. Morand would like to start treating patients at the St. Francis-St. George Hospital with brachytherapy sources as soon as possible.

Sincerely,

*Douglas R. Weitzel*

Douglas R. Weitzel, RT, CNMT  
Department Manager,  
Nuclear Medicine/Special Services

DRW:ph

enc.

Applicant	<i>July 19</i>	<b>RECEIVED</b> <b>JUL 19 1985</b> <b>REGION III</b>
Check No.	<i>79373</i>	
Amount/Fee Category	<i>P. 1.20</i>	
Type of Fee	<i>7C and</i>	
Date Check Rec'd	<i>7/26/85</i>	
Received By	<i>[Signature]</i>	

8508220252 850725  
REG3 LIC30  
34-00789-01 PDR

CONTROL NO. 7 9373

JUL 19 1985

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License number

34-13995-01

Docket or Reference number

Amendment No. 15

Providence Hospital  
Dept. of Nuclear Medicine  
2446 Kipling Ave.  
Cincinnati, OH 45239

In accordance with letter dated May 15, 1984, License Number 34-13995-01 is amended as follows:

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Vincent J. Seiwert, M.D.

All, except Group VI

Henry J. Kenkel, M.D.

All, except Group VI

John D. Looper, M.D.

Group VI

Phosphorus-32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions

~~Thomas M. Morand, M.D.~~

~~Group VI~~

~~Phosphorus-32 (colloidal) chromic phosphate for intracavitary treatment of malignant effusions~~

For the U.S. Nuclear Regulatory Commission

Date June 11, 1984

Original Signed  
By George M. McCann  
Materials Licensing Section, Region III

COPY 5

U. S. NUCLEAR REGULATORY COMMISSION  
MATERIALS LICENSEPage 1 of 5 Pages  
Amendment Number 09

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 36, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s); and to import such byproduct and source material. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954 as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Providence Hospital Department of Nuclear Medicine 2. 2446 Kipling Avenue Cincinnati, Ohio 45239		In accordance with application dated March 25, 1981, 3. License number 34-13995-01 is amended in its entirety to read as follows: 4. Expiration date September 30, 1986 5. Docket or Reference No.	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.	
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 6 curies of each byproduct material authorized in Subitem 6.B.	
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.	
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.	

CONTROL NO. 7 937 3